Drugs / Recombinant human insulin like growth factor-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00720122 | Jul 2008 → Oct 2011 | disease of bone structure | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human insulin like growth factor-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00720122 ↗ |
| Known as | rhIGF-1 | “Recombinant human insulin like growth factor-1 (rhIGF-1)” NCT00720122 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human insulin-like growth factor 1 (rhIGF-1) treatment” NCT00720122 ↗ |